Eli Lilly specifies guidance for this year's revenue
The USD 200m increase in the estimated revenue from products within Eli Lilly's core business, leads the US company to specify its guidance for the 2021 revenue. Now, the pharmaceutical company expects a revenue in the range of USD 26.8bn-27.4bn.
.jpg)
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
On Tuesday, US pharmaceutical company Eli Lilly detailed its guidance for the company's revenue for 2021 in connection with the publication of the pharmaceutical company's Q2 report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer and Moderna raise prices for coronavirus vaccines
For subscribers
Pfizer upgrades guidance for sales of covid-19 vaccine
For subscribers
